Daniel Spiegelman (EVP & CFO)
Brian R. Mueller (SVP, finance & CAO)
Products
Kuvan
Naglazyme
Aldurazyme
Firdapse
Vimizim
Brineura
Palynziq
Revenue
US$1.860 Billion (Fiscal Year Ended December 31, 2020)[2]
Operating income
–US$36.765 Million (Fiscal Year Ended December 31, 2020)[2]
Net income
US$0.859 Billion (Fiscal Year Ended December 31, 2020)[2]
Total assets
US$5.848 Billion (Fiscal Year Ended December 31, 2020)[2]
Total equity
US$4.106 Billion (Fiscal Year Ended December 31, 2020)[2]
Number of employees
2,581 (2017)
Website
biomarin.com
Footnotes / references [3]
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).[4][5]
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
^"Leadership Team". Biomarin. Retrieved 5 December 2023.
^ abcde"BioMarin Pharmaceutical Inc. 2020 Annual Report". app.quotemedia.com. 31 December 2020. Retrieved 20 November 2021.
^"US SEC: Form 10-K BioMarin Pharmaceutical Inc". U.S. Securities and Exchange Commission. Retrieved March 31, 2018.
^BruceCockburnVEVO (2011-12-15), Bruce Cockburn - Call It Democracy, archived from the original on 2021-12-19, retrieved 2019-04-18
^"'A wonder drug helped me eat - then I had to go without'". 17 April 2019.
and 27 Related for: BioMarin Pharmaceutical information
BioMarinPharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United...
digestive system if taken by mouth. Vosoritide was developed by BioMarinPharmaceutical and got orphan drug status in the US as well as the European Union...
therapy used for the treatment of hemophilia A. It was developed by BioMarinPharmaceutical. Valoctocogene roxaparvovec is made of a virus (AAV5) that has...
investigational drugs on behalf of terminally ill patients. In 2013, BioMarinPharmaceutical was at the center of a high-profile debate regarding expanded access...
with Kuvan is US$100,000 per year. BioMarin holds the patent for Kuvan until at least 2024, but Par Pharmaceutical has a right to produce a generic version...
which was developed through a series of companies ending with BioMarinPharmaceutical which obtained European approval in 2009 under the trade name Firdapse...
Merck revealed it would return the rights of the Kuvan drug to BioMarinPharmaceutical Inc. The drug is effective in the treatment of the rare genetic...
produced by BioMarin for use in Type I MPS. In May 2005, galsulfase[Naglazyme®], a recombinant enzyme replacement therapy also produced by Biomarin was approved...
of continued use of this drug. Cerliponase alfa is developed by BioMarinPharmaceutical and the drug application was granted both orphan drug designation...
synthetic version of this enzyme. Elosulfase alfa was developed by BioMarinPharmaceutical Inc. and approved for use in the US by the Food and Drug Administration...
April 2013. "Lambert-Eaton Myasthenic Syndrome: About". LEMS.com. BioMarinPharmaceutical Inc. Archived from the original on 20 January 2013. Retrieved 18...
Santa Clara 23andMe – Mountain View Anthera Pharmaceuticals – Hayward BioMarinPharmaceutical – San Rafael Bio-Rad Laboratories – Hercules Buck Institute...
including a library of histone deacetylase inhibitor compounds, to BioMarinPharmaceutical for US$2,000,000 and future milestone and royalty payments. Development...
next generation sequencing assays. Talazoparib was developed by BioMarinPharmaceutical Inc. and Medivation Inc. acquired all worldwide rights to talazoparib...
Aldurazyme by BioMarinPharmaceutical and Genzyme N-acetylgalactosamine-4-sulfatase (rhASB; galsulfase): Naglazyme by BioMarinPharmaceutical Dornase alfa...
Chief Scientific Officer and Chief Scientific Strategy Officer at BioMarinPharmaceutical and senior vice president at GlaxoSmithKline, where he worked to...
Niemann–Pick disease, type C, forcing the company to restructure. BioMarinPharmaceutical lost over 30% of its value when a CRL was issued in respect of...
ovaries by recombinant DNA technology, Aldurazyme is manufactured by BioMarinPharmaceutical Inc. and distributed by Genzyme Corporation (a subsidiary of Sanofi)...
blood Phe concentrations. The FDA granted approval of Palynziq to BioMarinPharmaceutical. "Palynziq". Therapeutic Goods Administration (TGA). 23 July 2021...
resulting in a sharp drop in its share price. In November 2014, BioMarinPharmaceutical agreed to pay up to $840 million to acquire Prosensa. In January...
Medical Center, continuing through his role as chief medical officer of BioMarin and as founder of the EveryLife Foundation. He became the chief executive...
Immunodeficiency". AP NEWS. 2020-04-20. Retrieved 2021-07-02. "Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast...
Global Information
US$1.860 Billion (Fiscal Year Ended December 31, 2020)[2]